【摘要】 目的:评价帕利哌酮缓释片治疗首发或复发精神分裂症的疗效和安全性。方法:用帕利哌酮缓释片治疗首发和复发精神分裂症共44例,疗程8周,用阳性症状和阴性症状量表(PANSS)和副反应量表(TESS)评定疗效及不良反应。结果:完成8周治疗的44例首发和复发精神分裂症患者的疗效为:痊愈21例(47.8%)、显著进步13例(29.5%)、进步6例(13.6%)、无效4例(9.1%),总有效率为90.9%;不良反应轻微。结论:帕利哌酮缓释片治疗精神分裂症临床疗效较好,安全性较高,依从性较佳,值得在临床一线广泛应用。更多还原

【Abstract】 Objective:To determine the clinical efficacy and safety of paliperidone in the treatment of schizophrenia.Methods:44 patients with first episode schizophrenia were treated with olanzapine for 8 weeks,and assessed with PANSS and TESS for the efficacy and safety.Results: 44 cases who completed the 8 weeks treatment,21 cases(47.8%) were cured,13 cases(29.5%)were significantly improved,6cases(13.6%)improved and 4 cases(9.1%)had no response.Total effective rate was 90.9%,with effect and mild obvious side effect.Conclusions: The study suggests that paliperidone is a safe,effective agent in the treatment of schizophrenia.更多还原